Agenda Details

This session will be tailored to help ASGCT’s Annual Meeting audience (i.e. mostly not Medicaid experts) understand current access issues within the Medicaid system and explore solutions to better accommodate the exponential pipeline of gene and cell therapies. The current Medicaid framework was built on the chronic care model, and is thus unequipped to handle anticipated CGT approvals with high upfront costs and projected durable benefits. Considering Medicaid is expected to play a significant role for many of the disease targets in the CGT pipeline, from sickle cell to Duchenne, the system will need to grapple with the existing barriers to access now to ensure equitable patient care.